Evidence map›Paper›PMID 33379189›Full record

ReviewCancers2020

3D Culture Systems for Exploring Cancer Immunology.

Allison A Fitzgerald, Eric Li, Louis M Weiner

Abstract readReview
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Real-Time Visualization of Endogenous HChemical & biomedical imaging · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. iScience · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Allison A FitzgeraldDepartment of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.ORCID 0000-0002-2814-0481
Eric LiDepartment of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Louis M WeinerDepartment of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.ORCID 0000-0001-5192-0710

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
TARGETED IMMUNOTHERAPY USING BISPECIFIC ANTIBODIESR01CA050633 · NCI · GEORGETOWN UNIVERSITY · PI WEINER, LOUIS M. · 1989 to 2018
$6.5M
The Potential Role of Firboblast Activation Protein as a Natural Killer Cell Immune Checkpoint in Pancreatic CancerF30CA239441 · NCI · GEORGETOWN UNIVERSITY · PI O'CONNELL, ALLISON · 2019 to 2023
$196k
NCI NIH HHS F30 CA239441NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA050633NIH HHS F30 CA239441NIH HHS P30 CA051008NIH HHS R01 CA050633
6 · The paper itself

Abstract

Cancer immunotherapy has revolutionized cancer treatment, spurring extensive investigation into cancer immunology and how to exploit this biology for therapeutic benefit. Current methods to investigate cancer-immune cell interactions and develop novel drug therapies rely on either two-dimensional (2D) culture systems or murine models. However, three-dimensional (3D) culture systems provide a potentially superior alternative model to both 2D and murine approaches. As opposed to 2D models, 3D models are more physiologically relevant and better replicate tumor complexities. Compared to murine models, 3D models are cheaper, faster, and can study the human immune system. In this review, we discuss the most common 3D culture systems-spheroids, organoids, and microfluidic chips-and detail how these systems have advanced our understanding of cancer immunology.

Indexed as

immunotherapymicrofluidic chipsorganoidsspheroidsthree-dimensional culturetumor immunology

Identifiers

PMID33379189
PMCPMC7795162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.